TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway

TuHURA Biosciences, Inc./NV

Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.
R&D expenses $4.9M (Q3 2025) vs $2.9M (Q3 2024); 9-month net cash outflow $22.1M vs $12.1M.
DOR technology selected for oral presentation at ASH 2025 Annual Meeting in December.
Appointed Dr. Michael Turner as Vice President of Immunology in November 2025.
Filed $50M ATM facility in November 2025; not yet effective.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.